These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3720177)

  • 1. Concomitant food intake can increase the bioavailability of propranolol by transient inhibition of its presystemic primary conjugation.
    Liedholm H; Melander A
    Clin Pharmacol Ther; 1986 Jul; 40(1):29-36. PubMed ID: 3720177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of food intake on presystemic clearance of drugs.
    Melander A; McLean A
    Clin Pharmacokinet; 1983; 8(4):286-96. PubMed ID: 6352137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stable oral availability of sustained release propranolol when co-administered with hydralazine or food: evidence implicating substrate delivery rate as a determinant of presystemic drug interactions.
    Byrne AJ; McNeil JJ; Harrison PM; Louis W; Tonkin AM; McLean AJ
    Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):45S-50S. PubMed ID: 6743474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of acute alcohol administration on propranolol absorption.
    Grabowski BS; Cady WJ; Young WW; Emery JF
    Int J Clin Pharmacol Ther Toxicol; 1980 Jul; 18(7):317-9. PubMed ID: 7429677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Propranolol: pooled Michaelis-Menten parameters and the effect of input rate on bioavailability.
    Wagner JG
    Clin Pharmacol Ther; 1985 May; 37(5):481-7. PubMed ID: 3987171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No stereoselective first-pass hepatic extraction of propranolol.
    Jackman GP; McLean AJ; Jennings GL; Bobik A
    Clin Pharmacol Ther; 1981 Sep; 30(3):291-6. PubMed ID: 7273593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct measurement of propranolol bioavailability during accumulation to steady-state.
    Wood AJ; Carr K; Vestal RE; Belcher S; Wilkinson GR; Shand DG
    Br J Clin Pharmacol; 1978 Oct; 6(4):345-50. PubMed ID: 698031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic studies with a new controlled-release formulation of propranolol in normal volunteers: a comparison with other commercially available formulations.
    Perucca E; Grimaldi R; Gatti G; Caravaggi M; Crema F; Lecchini S; Frigo GM
    Br J Clin Pharmacol; 1984 Jul; 18(1):37-43. PubMed ID: 6743489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonlinear pharmacokinetics of unbound propranolol after oral administration.
    Straka RJ; Lalonde RL; Pieper JA; Bottorff MB; Mirvis DM
    J Pharm Sci; 1987 Jul; 76(7):521-4. PubMed ID: 3668812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereoselective oral bioavailability of (+/-)-propranolol in the dog. A GC-MS study using a stable isotope technique.
    Walle T; Walle UK
    Res Commun Chem Pathol Pharmacol; 1979 Mar; 23(3):453-64. PubMed ID: 461970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms and variations in the food effect on propranolol bioavailability.
    Liedholm H; Wåhlin-Boll E; Melander A
    Eur J Clin Pharmacol; 1990; 38(5):469-75. PubMed ID: 2379531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presystemic and systemic glucuronidation of propranolol.
    Walle T; Fagan TC; Conradi EC; Walle UK; Gaffney TE
    Clin Pharmacol Ther; 1979 Aug; 26(2):167-72. PubMed ID: 455886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increase in plasma propranolol caused by nicardipine is dependent on the delivery rate of propranolol.
    Vercruysse I; Massart DL; Dupont AG
    Eur J Clin Pharmacol; 1995; 49(1-2):121-5. PubMed ID: 8751033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereoselective increase in propranolol bioavailability during chronic dosing in the dog.
    Bai SA; Wilson MJ; Walle UK; Walle T
    J Pharmacol Exp Ther; 1983 Nov; 227(2):360-4. PubMed ID: 6631718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of food intake on the bioavailability of zuclopenthixol.
    Aaes-Jørgensen T; Liedholm H; Melander A
    Drug Nutr Interact; 1987; 5(3):157-60. PubMed ID: 3691322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erratic absorption of a slow-release theophylline sprinkle product.
    Pedersen S; Møller-Petersen J
    Pediatrics; 1984 Oct; 74(4):534-8. PubMed ID: 6483520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of the bioavailability of propranolol and metoprolol by food.
    Melander A; Danielson K; Scherstén B; Wåhlin E
    Clin Pharmacol Ther; 1977 Jul; 22(1):108-12. PubMed ID: 872491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of glucuronidation of propranolol following oral administration in humans.
    Midha KK; Roscoe RM; Wilson TW; Cooper JK; Loo JC; Ho-Ngoc A; McGilveray IJ
    Biopharm Drug Dispos; 1983; 4(4):331-8. PubMed ID: 6661512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug input rate from the GI-tract. Michaelis-Menten kinetics and the bioavailability of slow release verapamil and nifedipine.
    Woodcock BG; Menke G; Fischer A; Köhne H; Rietbrock N
    Drug Des Deliv; 1988 May; 2(4):299-310. PubMed ID: 3255321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction between oral hydralazine and propranolol. I. Changes in absorption, presystemic clearance and splanchnic blood flow.
    Heinzow B; Corbett H; Constantinides S; Bourne R; McLean AJ
    J Pharmacol Exp Ther; 1984 May; 229(2):509-14. PubMed ID: 6716273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.